Partnership Opportunities

Why Partner?

The 2nd Annual Mitochondria-Targeted Drug Development Summit will unite leading experts and top

organizations in Boston, to accelerate the discovery and development of novel drugs targeting mitochondrial functions for chronic diseases.

This is your opportunity to collaborate with key decision-makers to overcome their current challenges halting further progress in this emerging space.

As drug developers targeting mitochondria dysfunction mature and progress into clinical development, they are currently seeking help with:

21640_-_Mitochondria_Targeted_Therapeutics_Favicon-removebg-preview (1)

Contract Research – Can you accelerate and support preclinical and clinical R&D biopharma to help make therapeutics for (mito-targeted) chronic diseases a reality for patients?

21640_-_Mitochondria_Targeted_Therapeutics_Favicon-removebg-preview (1)

Preclinical Services – Can you provide novel solutions to existing preclinical model challenges to develop effective therapeutics that target mitochondria for chronic diseases?

21640_-_Mitochondria_Targeted_Therapeutics_Favicon-removebg-preview (1)

Equipment & Service Providers – Do you have equipment or services that can allow developers to run mitochondrial function assays, improve live cell imaging, provide cell-based phenotypic testing technologies?

Hear what our 2021 attendees had to say about the inaugural Mitochondria-Targeted Drug Development Summit:

21640_-_Mitochondria_Targeted_Therapeutics_Favicon-removebg-preview (1)

A great deep dive in the biology of mitochondria and the current therapeutic approaches

Business Development, Amazentis

21640_-_Mitochondria_Targeted_Therapeutics_Favicon-removebg-preview (1)

Having the second speaker slot on the opening day was a big plus. The scientific presentations were excellent, exceeding my expectations.

Founder, Biolog Inc

Email sponsor@hansonwade.com to learn how we can help you achieve your business goals faster, more effectively, and more cost-efficiently for 2022 and beyond.